• 1. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 3. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 4. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Benzimidazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles

Recent Advances in the Study of Methyl 2-amino-1H-benzimidazole-4-carboxylate (CAS: 910122-42-8) and Its Applications in Chemical Biology and Pharmaceutical Research

Methyl 2-amino-1H-benzimidazole-4-carboxylate (CAS: 910122-42-8) is a benzimidazole derivative that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound serves as a key intermediate in the synthesis of various biologically active molecules, including kinase inhibitors, antimicrobial agents, and anticancer drugs. The unique structural features of this molecule, such as the presence of both amino and carboxylate functional groups, make it a valuable scaffold for drug discovery and development.

Recent studies have focused on exploring the synthetic pathways and biological activities of methyl 2-amino-1H-benzimidazole-4-carboxylate. A 2023 study published in the *Journal of Medicinal Chemistry* demonstrated its potential as a precursor for the development of novel kinase inhibitors targeting cancer-related pathways. The researchers utilized a multi-step synthetic approach to derivatize the compound, resulting in a series of analogs with improved potency and selectivity against specific kinase targets. These findings highlight the compound's potential in oncology drug discovery.

In addition to its role in kinase inhibitor development, methyl 2-amino-1H-benzimidazole-4-carboxylate has also been investigated for its antimicrobial properties. A 2022 study in *Bioorganic & Medicinal Chemistry Letters* reported that derivatives of this compound exhibited significant activity against drug-resistant bacterial strains, including methicillin-resistant *Staphylococcus aureus* (MRSA). The study attributed this activity to the compound's ability to disrupt bacterial cell wall synthesis, suggesting its potential as a lead compound for new antibiotic development.

Another area of interest is the compound's application in the synthesis of heterocyclic compounds with diverse biological activities. A 2023 review in *Current Organic Chemistry* summarized recent advances in the use of methyl 2-amino-1H-benzimidazole-4-carboxylate as a building block for the construction of fused heterocycles, which are prevalent in many FDA-approved drugs. The review emphasized the compound's versatility and efficiency in facilitating complex molecular transformations.

Despite these promising developments, challenges remain in optimizing the pharmacokinetic properties of methyl 2-amino-1H-benzimidazole-4-carboxylate derivatives. A 2023 study in *European Journal of Pharmaceutical Sciences* investigated the metabolic stability and bioavailability of these compounds, identifying key structural modifications that could enhance their drug-like properties. These findings provide valuable insights for future medicinal chemistry efforts aimed at developing clinically viable candidates.

In conclusion, methyl 2-amino-1H-benzimidazole-4-carboxylate (CAS: 910122-42-8) continues to be a focal point of research in chemical biology and pharmaceutical sciences. Its diverse applications, from kinase inhibitors to antimicrobial agents, underscore its importance as a versatile scaffold for drug discovery. Ongoing studies are expected to further elucidate its potential and address current limitations, paving the way for the development of novel therapeutic agents.

• 37619-25-3(methyl 1H-1,3-benzodiazole-4-carboxylate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)